The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The impact of 5HT3RA antiemetics on the incidence of chemotherapy-induced nausea and vomiting (CINV), treatment adherence, and delay of therapy in early-stage breast cancer (BC) patients treated with moderately/highly emetogenic chemotherapy (MEC/HEC).
Hope S. Rugo
Research Funding - BiPar Sciences; Eisai; Genentech/Roche; GlaxoSmithKline; ImClone Systems; Merck; Novartis; Sanofi
Swetha Palli
No relevant relationships to disclose
Michael Grabner
No relevant relationships to disclose
Ralph A. Quimbo
No relevant relationships to disclose
Russell L. Knoth
Employment or Leadership Position - Eisai